CHEMBL1401

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
gptkbp:ATCCode gptkb:C07AB03
gptkbp:bioavailability 50% (oral)
gptkbp:CASNumber gptkb:29122-68-7
gptkbp:contraindication bradycardia
cardiogenic shock
second- or third-degree heart block
gptkbp:developedBy gptkb:ICI_Pharmaceuticals
gptkbp:drugClass selective beta-1 blocker
gptkbp:eliminationHalfLife 6-7 hours
gptkbp:excretion renal
gptkbp:hasInChIKey METKIMKYRPQLGS-UHFFFAOYSA-N
gptkbp:hasLogP 0.16
gptkbp:hasMolecularFormula C14H22N2O3
gptkbp:hasSMILES CC(C)NCC(COC1=CC=CC=C1O)O
gptkbp:hasTherapeuticUse antianginal agent
antiarrhythmic agent
antihypertensive agent
gptkbp:hasUNII 50VV3VW0TI
https://www.w3.org/2000/01/rdf-schema#label CHEMBL1401
gptkbp:indication gptkb:arrhythmias
myocardial infarction
hypertension
angina pectoris
gptkbp:isApprovedDrug true
gptkbp:legalStatus Rx-only (US)
POM (UK)
gptkbp:listedOn gptkb:WHO_Model_List_of_Essential_Medicines
gptkbp:marketedIn gptkb:United_Kingdom
gptkb:United_States
gptkbp:mechanismOfAction beta-1 adrenergic receptor antagonist
gptkbp:meltingPoint 152-155°C
gptkbp:molecularWeight 266.34
gptkbp:name gptkb:Atenolol
gptkbp:pregnancyCategory C (US)
gptkbp:proteinBinding 6-16%
gptkbp:PubChem_CID gptkb:CHEMBL1401
2162
DB00335
CHEBI:2268
gptkbp:routeOfAdministration oral
intravenous
gptkbp:sideEffect dizziness
fatigue
bradycardia
cold extremities
gptkbp:synonym gptkb:Atenololum
gptkb:Tenormin
gptkbp:target gptkb:Beta-1_adrenergic_receptor
gptkbp:wasFirstApproved 1976
gptkbp:bfsParent gptkb:menadione
gptkbp:bfsLayer 5